Please ensure Javascript is enabled for purposes of website accessibility
Amicus Therapeutics Stock Quote

Amicus Therapeutics (NASDAQ: FOLD)

$13.25
(-1.9%)
-$0.26
Price as of February 3, 2023, 4:00 p.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Amicus Therapeutics Returns vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
FOLD +49.72% -19.21% -4.17% -8%
S&P -7.62% +49.76% +8.40% +170%

Amicus Therapeutics Company Info

A global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel high-quality medicines for people living with rare metabolic diseases. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases, including an industry leading rare disease gene therapy portfolio.

News & Analysis

The Fool has written over 100 articles on Amicus Therapeutics.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
413%
 
S&P 500 Returns
121%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 02/04/2023.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.